SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Genzyme Tissue Repair (GZTR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Linda Kaplan who wrote (2028)7/19/1998 6:12:00 PM
From: Bob Jagow  Read Replies (1) of 2553
 
BW doesn't seem that impressed, Linda, I'd go for AAPL ;) -Bob

A knee-repair product called Carticel, approved by the FDA
last August, uses somewhat the same principle. Made by
Genzyme Tissue Repair, Carticel grows cartilage cells
removed from the patient in the lab and then surgically
reimplants them in the knee. No matrix is provided, however,
so the cells can only be used to repair small rents. To replace
the entire meniscus--that's the C-shaped pad in the knee
between the thigh bone and shin bone--ReGen Biologics Inc.
of Redwood City, Calif., is in clinical trials with a collagen
scaffold in the shape of the meniscus. The pad is implanted
in the knee to encourage regeneration of the patient's
cartilage. Going a step further, Advanced Tissue Sciences is
in preclinical trials with a meniscus-shaped cartilage grown in
the lab that's meant to work in anyone. It hopes to start
human tests by yearend.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News